Abstract: Objective To evaluate the efficacy of bipheny dicarboxylate and glucurolactone on prevention and treatment of antituberculous drug hepatoxicity.Methods 124 hospitalized HBsAg positive patients with pulmonary tuberculosis were randomized to bipheny dicarboxylate and glucurolactone of control group in addition to 2HRZE/4HR therapy.Results Middle level reversible serum aspartate transaminase elevation (17.0% vs 35.2% P<0.05) occurred more commonly in the 71 patients randomized to the control group. There exists statistically significant difference between the two groups.Meanwhile 116 HBsAg negative patients with pulmonary tuberculosis were observed and only 8.6% of them occurred middle level reversible serum aspartate transaminase elevation during antituberculous therapy.Conclusion Medicamentous liver lesion may occurred more commonly in HBsAg positive patients after antituberculous therapy.bipheny dicarboxylate and glucurolactone can only prevent and cure part of them.Drug anaphylactic reaction may play a role in medicamentous liver lesion.

Key words: Tuberculosis, pulmonary, Bipheny Dicarboxylate, Glucurolactone